PAR PHARMACEUTICAL | 27,709 Euro | -0,139 -0,50 % | |
| WKN: A0B5R1 ISIN: US69888P1066 Ticker-Symbol: PZJ | Frankfurt | 10.02.12 | 08:02 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 06.02. | Robbins Umeda LLP Announces an Investigation of Par Pharmaceutical Companies, Inc. | 31 | Business Wire | |
| Shareholder rights firm Robbins
Umeda LLP is investigating possible breaches of fiduciary duty and
other violations of the law by certain officers and directors at Par... Mehr lesen zu: Robbins Umeda LLP Announces an Investigation of Par Pharmaceutical Companies, Inc. | ||||
| 31.01. | Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2011 Results on February 28, 2012 | 6 | PR Newswire | |
| WOODCLIFF LAKE, N.J., Jan. 31, 2012 /PRNewswire/ --Par Pharmaceutical Companies, Inc. (NYSE:PRX) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2012... Mehr lesen zu: Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2011 Results on February 28, 2012 | ||||
| 05.12. | PAR PHARMACEUTICAL COMPANIES, INC. - 10-Q/A, Quarterly Report | 1 | SEC Filings | |
| 05.12. | Par Pharmaceutical to Host Analyst Day on January 6, 2012 | 26 | PR Newswire | |
| WOODCLIFF LAKE, N.J., Dec. 5, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) will hold an Analyst Day from 9:00am to 12:00pm EST on Friday, January 6, 2012 at the Millennium... Mehr lesen zu: Par Pharmaceutical to Host Analyst Day on January 6, 2012 | ||||
| 25.11. | UPDATE 1-Activist investor seeks strategic alternatives for Par Pharma | 3 | Reuters.com | |
| 22.11. | Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer | 11 | PR Newswire | |
| WOODCLIFF LAKE, N.J., Nov. 22, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its board of directors has approved the promotions of Thomas J. Haughey to the... Mehr lesen zu: Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer | ||||
| 17.11. | Par Pharma (PRX) Completes $410M Acquisition of Anchen Pharma | - | StreetInsider.com | |
| 17.11. | Par Pharmaceutical Completes Acquisition of Anchen | 23 | PR Newswire | |
| WOODCLIFF LAKE, N.J., Nov. 17, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has completed its acquisition of Anchen Pharmaceuticals, a privately-held... Mehr lesen zu: Par Pharmaceutical Completes Acquisition of Anchen | ||||
| 02.11. | UPDATE 1-Par Pharma Q3 edges past Street | - | Reuters.com | |
| 02.11. | Par Pharmaceutical Companies Reports Third Quarter 2011 Results | 31 | PR Newswire | |
| WOODCLIFF LAKE, N.J., Nov. 2, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported results for the third quarter ended September 30, 2011.
For the third quarter ended... Mehr lesen zu: Par Pharmaceutical Companies Reports Third Quarter 2011 Results | ||||
| 24.10. | Par Pharmaceutical Begins Shipment of Generic Zyprexa® Zydis® | 38 | PR Newswire | |
| WOODCLIFF LAKE, N.J., Oct. 24, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 5mg, 10mg, 15mg, and 20mg strengths of olanzapine orally... Mehr lesen zu: Par Pharmaceutical Begins Shipment of Generic Zyprexa® Zydis® | ||||
| 18.10. | Par Pharmaceutical Buys Rights To Three Generic Products From Teva | 50 | AFX News | |
| PETAH TIKVA (dpa-AFX) - Par Pharmaceutical Companies, Inc. (PRX) said it
acquired rights to three products from Teva Pharmaceuticals (TEVA) in connection
with Teva's acquisition of Cephalon.... Mehr lesen zu: Par Pharmaceutical Buys Rights To Three Generic Products From Teva | ||||
| 18.10. | Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals | 10 | PR Newswire | |
| WOODCLIFF LAKE, N.J., Oct. 18, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it acquired rights to three products from Teva Pharmaceuticals in connection... Mehr lesen zu: Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals | ||||
| 14.10. | Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES | 102 | PR Newswire | |
| WOODCLIFF LAKE, N.J., Oct. 14, 2011 /PRNewswire/ -- Par Pharmaceutical, Inc., the wholly-owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it filed a declaratory... Mehr lesen zu: Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES | ||||
| 07.10. | Expert's Economic Outlook, Global - Equity Research on Par Pharmaceutical Companies, Inc. and Targacept, Inc. | 18 | MarketWire | |
| MACAU -- (Marketwire) -- 10/07/11 -- Today, www.EquityMarketsInc.com announced its research report highlighting Par Pharmaceutical Companies, Inc. (NYSE: PRX) and Targacept, Inc. (NASDAQ: TRGT). Full... Mehr lesen zu: Expert's Economic Outlook, Global - Equity Research on Par Pharmaceutical Companies, Inc. and Targacept, Inc. | ||||
| 03.10. | Par Pharmaceutical Companies to Report Third Quarter 2011 Results on November 2, 2011 | 55 | PR Newswire | |
| WOODCLIFF LAKE, N.J., Oct. 3, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE:PRX) announced today that it will host a conference call and live webcast on Wednesday, November 2, 2011... Mehr lesen zu: Par Pharmaceutical Companies to Report Third Quarter 2011 Results on November 2, 2011 | ||||
| 03.10. | Global Situation & Resulting Influences - Research Report on Akorn, Inc. and Par Pharmaceutical Companies, Inc. | 11 | MarketWire | |
| MACAU -- (Marketwire) -- 10/03/11 -- Today, www.EquityMarketsInc.com announced its research report highlighting Akorn, Inc. (NASDAQ: AKRX) and Par Pharmaceutical Companies, Inc. (NYSE: PRX). Full... Mehr lesen zu: Global Situation & Resulting Influences - Research Report on Akorn, Inc. and Par Pharmaceutical Companies, Inc. | ||||
| 24.08. | UPDATE 1-Par Pharma to buy generic drugmaker for $410 mln | - | Reuters.com | |
| 24.08. | Par Pharmaceutical To Acquire Anchen Pharmaceuticals | 108 | PR Newswire | |
| WOODCLIFF LAKE, N.J., Aug. 24, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it entered into a definitive agreement to acquire Anchen Pharmaceuticals, a... Mehr lesen zu: Par Pharmaceutical To Acquire Anchen Pharmaceuticals | ||||
| 22.08. | The Zacks Analyst Blog Highlights: Par Pharmaceutical Companies, Intellipharmaceutics International, Celgene Corporation, Novartis AG and Elan Corporation plc | 63 | PR Newswire | |
| CHICAGO, Aug. 22, 2011 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting... Mehr lesen zu: The Zacks Analyst Blog Highlights: Par Pharmaceutical Companies, Intellipharmaceutics International, Celgene Corporation, Novartis AG and Elan Corporation plc | ||||
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
